This study aimed to compare physical activity (PA) indicators, metabolic biomarkers, and comorbidity, to investigate the relationship between PA indicators and metabolic biomarkers, comorbidity and to identify barriers to PA in patients with type 2 diabetes (T2DM) who are using oral hypoglycaemic agent (OHA) or combined OHA and insulin (OHAiN). Sixty-one patients were classified as patients using only OHA or combined OHAiN. Metabolic biomarkers (waist-to-hip ratio, body mass index (BMI), lipid profile, glycosylated haemoglobin (HbA1c), fasting blood glucose, comorbidity and PA indicators (self-reported PA, number of steps (NOS), 6-minute walking distance (6MWD)) were assessed. PA perceptions and reasons for inactivity were questioned. The comorbidity ( = .013), low-density lipoprotein-cholesterol ( = .026), total cholesterol ( = .008) and HbA1c ( = .020) were higher and PA level was lower ( = .007) in the OHAiN group. NOS was positively correlated with high-density lipoprotein-cholesterol ( = .037) and negatively correlated with BMI ( = .007). 6MWD was negatively correlated with BMI ( = .014) and comorbidity ( = .004) in the OHA group. BMI was a significant predictor of NOS (adjusted  = 0.242) and comorbidity for 6MWD (adjusted  = 0.250) in the OHA group. The majority of the patients (OHA = 34.3%, OHAiN = 42.3%) reported "lack of time" as the most common barrier to PA. This study showed that patients on OHAiN have lower PA levels, poorer metabolic profiles, and higher comorbidity rates than OHA users. PA indicators were related with some metabolic biomarkers and comorbidity in only OHA users. The most common reason for inactivity was "the lack of time" in both groups.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02701367.2019.1645269DOI Listing

Publication Analysis

Top Keywords

metabolic biomarkers
20
indicators metabolic
16
biomarkers comorbidity
16
comorbidity
9
physical activity
8
activity indicators
8
type diabetes
8
oha combined
8
negatively correlated
8
correlated bmi
8

Similar Publications

HER-2 SMASH.

Cancer Chemother Pharmacol

December 2024

Departments of Pharmacology, Medicine Faculty, Sivas Cumhuriyet University, Sivas, Türkiye.

Purpose: Human epidermal growth factor-2 (HER-2) targeted drugs are used in only HER-2 overexpressed cancers. However, only a small portion of these cancer types are HER-2 overexpressed. In this study, we aimed to upregulate HER-2 receptors in MCF-7 breast cancer and HT-29 colon cancer cell cultures, which these cells are not HER-2 upregulated in natural status.

View Article and Find Full Text PDF

Prognostic and immunological role of LASP2 in clear cell renal cell carcinoma.

Genes Genomics

December 2024

Department of Urology, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, No. 63, Huang Tang Road, Meizhou, 514031, Guangdong Province, People's Republic of China.

Background: Clear cell renal cell carcinoma (ccRCC) represents a common renal carcinoma subtype influenced by the immune microenvironment. LIM and SH3 Protein 2 (LASP2), an actin-binding protein within the nebulin family, contributes to cellular immunity and adhesion mechanisms.

Objective: This study aimed to clarify the immunological and prognostic relevance of LASP2 in ccRCC.

View Article and Find Full Text PDF

Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer.

Cancer Chemother Pharmacol

December 2024

Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.

Purpose: Cisplatin (CDDP) induces acute kidney injury (AKI) as a side effect during neoadjuvant chemotherapy (NAC). Urinary vanin-1 excretion may increase during CDDP treatment. We investigated whether urinary vanin-1 is an early biomarker for CDDP-induced AKI.

View Article and Find Full Text PDF

The increasing prevalence of obesity and metabolic disorders has created a significant demand for personalized devices that can effectively monitor fat metabolism. In this study, we developed an advanced breath analyzer system designed to provide real-time monitoring of exercise-induced fat burning by analyzing volatile organic compounds (VOCs) present in both oral and alveolar breath. Acetone in exhaled breath and β-hydroxybutyric acid (BOHB) in the blood are both biomarkers closely linked to the metabolic fat burning process occurring in the liver, particularly after exercise.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!